Lidia Oostvogels qualified as a medical doctor at Ghent University in Belgium in 1991 and then spent nine years in a clinical development role with Boehringer Ingelheim. She has been working in vaccine development for more than 20 years, first with GSK, where she became Senior Director, Clinical and Epidemiology Project Lead, and was involved in clinical development of rotavirus, meningococal, influenza and zoster vaccines. She went on to become Senior Vice President, Area Head for Infectious Diseases and Senior Vice President for Clinical Development for prophylactic vaccines with CureVac (mRNA vaccines). Since 2022, Lidia has been with MinervaX as Chief Medical Officer – developing a maternal GBS vaccine. In addition to her professional commitments, Lidia is passionate about public health advocacy. She enjoys art, reading, and traveling, which she believes enriches her perspective on global health challenges.